modelAmoxicillinAndBetaLactam

Diagram of AmoxicillinAndBetaLactam

Extends from Pharmacolibrary.Drugs.ATC.J.J01CR02.

Information

name:AmoxicillinAndBetaLactamaseInhibitor
ATC code:J01CR02
route:oral
compartments:1
dosage:500mg
volume of distribution:21.8L
clearance:12.3L/h
other parameters in model implementation

A combination antibacterial medication consisting of amoxicillin, a broad-spectrum penicillin antibiotic, and a beta-lactamase inhibitor (commonly clavulanic acid), which extends the spectrum of amoxicillin by inhibiting bacterial beta-lactamase enzymes. It is approved and widely used today for the treatment of infections such as respiratory tract infections, urinary tract infections, skin infections, and others caused by susceptible bacteria.

Pharmacokinetics

Pharmacokinetic parameters in healthy adult volunteers after a single oral administration of amoxicillin in combination with clavulanic acid.

References

  1. Mellon, G, et al., & Crémieux, AC (2020). Population pharmacokinetics and dosing simulations of amoxicillin in obese adults receiving co-amoxiclav. The Journal of antimicrobial chemotherapy 75(12) 3611–3618. DOI:10.1093/jac/dkaa368 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32888018

  2. Schouwenburg, S, et al., & Preijers, T (2025). A Pooled Population Pharmacokinetic Study of Oral and Intravenous Administration of Clavulanic Acid in Neonates and Infants: Targeting Effective Beta-Lactamase Inhibition. Clinical pharmacology and therapeutics 117(1) 193–202. DOI:10.1002/cpt.3423 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39205386

  3. de Velde, F, et al., & Mouton, JW (2016). Non-linear absorption pharmacokinetics of amoxicillin: consequences for dosing regimens and clinical breakpoints. The Journal of antimicrobial chemotherapy 71(10) 2909–2917. DOI:10.1093/jac/dkw226 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27330071

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.TransferRateka (from PK_1C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_1C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)